Jinyyy的个人主页 - 老虎社区

Jinyyy

暂无个人介绍

IP属地：未知

125关注

69粉丝

0主题

0勋章

2021-12-21

$Moderna, Inc.(MRNA)$I don’t even know who is selling this? Haha

2021-12-21

Fly

Moderna could be ready to develop Omicron booster in weeks - CEO

2021-12-21

$Moderna, Inc.(MRNA)$https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&utm_medium=social&utm_source=facebook&fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk

2021-12-17

Hi this is for event

2021-12-17

Isn’t this old news

Moderna COVID-19 shot more likely to cause heart inflammation than Pfizer's, study shows

2021-12-07

$Moderna, Inc.(MRNA)$Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.

2021-12-03

$Moderna, Inc.(MRNA)$Haha once again people selling even with good news. [Miser]

2021-12-01

Buy both

Moderna or Pfizer Stock: Which to Buy as Omicron Spreads?

2021-12-01

$Moderna, Inc.(MRNA)$Paper hand

2021-11-30

$Novavax(NVAX)$price is trading too high when is not authorised. I would close position to get into moderna or Pfizer

2021-11-30

$Moderna, Inc.(MRNA)$Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year

2021-11-29

$Moderna, Inc.(MRNA)$Is time to buy in because of omicron haha:)

2021-11-17

$Palantir Technologies Inc.(PLTR)$Growth is growth. Will you rather invest in a company that make loss or company with so called maybe decelerating growth. My view is palantir has the potential to work with different big companies.

2021-11-11

$Histogenics(OCGN)$Timeline is very important. Clearly, if ocugen has not gotten approval by now then is really time to leave if you have profit. Those who hold might want to get option to sell … I foresee is going down

2021-11-11

$Rivian Automotive, Inc.(RIVN)$Lol if u havealready profit, please run. This is very risky~

2021-11-10

$Rivian Automotive, Inc.(RIVN)$The price is too high. Poor valuation

2021-11-09

$Intel(INTC)$Jokers selling. Haha. Sometime is hard to find news

2021-11-09

$GLOBALFOUNDRIES Inc.(GFS)$IPO surge is over. Thanks it was a good run:) 30% from 46+. Regret didn’t get in more !

2021-11-08

Isn’t this good news haha

Why Are GlobalFoundries Shares Trading Lower Today?

2021-11-08

$GLOBALFOUNDRIES Inc.(GFS)$Hodl and push to 70

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3581759532939362,"uuid":"3581759532939362","gmtCreate":1618665962961,"gmtModify":1618665962961,"name":"Jinyyy","pinyin":"jinyyy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":69,"headSize":125,"tweetSize":121,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.02","exceedPercentage":"60.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691019636,"gmtCreate":1640097345384,"gmtModify":1640097346158,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>I don’t even know who is selling this? Haha&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>I don’t even know who is selling this? Haha&nbsp;","text":"$Moderna, Inc.(MRNA)$I don’t even know who is selling this? Haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/691019636","isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693790079,"gmtCreate":1640073868484,"gmtModify":1640073869178,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Fly","listText":"Fly","text":"Fly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693790079","repostId":"1140916492","repostType":2,"repost":{"id":"1140916492","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640072746,"share":"https://www.laohu8.com/m/news/1140916492?lang=&edition=full","pubTime":"2021-12-21 15:45","market":"us","language":"en","title":"Moderna could be ready to develop Omicron booster in weeks - CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1140916492","media":"Reuters","summary":"ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing","content":"<p>ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few weeks, Chief Executive Stephane Bancel said in an interview.</p>\n<p>Moderna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose&nbsp;of its current mRNA-1273 vaccine.</p>\n<p>\"It only needs minor adjustments for Omicron. I don't expect any problems,\" Bancel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.</p>\n<p>The company was now awaiting important information on the variant to begin development.</p>\n<p>\"That will take another week or two,\" Bancel said.</p>\n<p>\"It will take a few months before we can produce 500 million doses after (regulatory) approval. But our capacities are much higher today than a year ago,\" he said.</p>\n<p>If approval bodies such as the U.S. Food and Drug Administration and Switzerland's Swissmedic require further studies, that would add at least three months.</p>\n<p>\"Some authorities want a study, others are still undecided. In my opinion, it depends very much on how severely the disease progresses,\" he said.</p>\n<p>Following delivery delays and lags in production in early 2021, Moderna is now able to keep up with production targets and deliver orders on time.</p>\n<p>The company made between 700 million and 800 million COVID-19 vaccine doses this year, and expects to produce a higher number in 2022, boosting production from 100 million doses a month to 150 million.</p>\n<p>Additional production lines that are being built via a deal with Swiss-based drugmaker Lonza will become operational in the first quarter of 2022, boosting production, he said, adding the company for the first time had 30 million doses in stock.</p>\n<p>After signing preliminary agreements with Canada and Australia, Moderna has begun discussions with Switzerland over a so-called vaccine subscription that could ensure supply as it develops novel mRNA vaccine, and is interested in deepening ties with other regimes.</p>\n<p>\"We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease that is fatal in the elderly and young children,\" Bancel said.</p>\n<p>\"We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.\"</p>\n<p>That would give those countries priority supply in the event of a new pandemic, he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna could be ready to develop Omicron booster in weeks - CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna could be ready to develop Omicron booster in weeks - CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-21 15:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few weeks, Chief Executive Stephane Bancel said in an interview.</p>\n<p>Moderna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose&nbsp;of its current mRNA-1273 vaccine.</p>\n<p>\"It only needs minor adjustments for Omicron. I don't expect any problems,\" Bancel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.</p>\n<p>The company was now awaiting important information on the variant to begin development.</p>\n<p>\"That will take another week or two,\" Bancel said.</p>\n<p>\"It will take a few months before we can produce 500 million doses after (regulatory) approval. But our capacities are much higher today than a year ago,\" he said.</p>\n<p>If approval bodies such as the U.S. Food and Drug Administration and Switzerland's Swissmedic require further studies, that would add at least three months.</p>\n<p>\"Some authorities want a study, others are still undecided. In my opinion, it depends very much on how severely the disease progresses,\" he said.</p>\n<p>Following delivery delays and lags in production in early 2021, Moderna is now able to keep up with production targets and deliver orders on time.</p>\n<p>The company made between 700 million and 800 million COVID-19 vaccine doses this year, and expects to produce a higher number in 2022, boosting production from 100 million doses a month to 150 million.</p>\n<p>Additional production lines that are being built via a deal with Swiss-based drugmaker Lonza will become operational in the first quarter of 2022, boosting production, he said, adding the company for the first time had 30 million doses in stock.</p>\n<p>After signing preliminary agreements with Canada and Australia, Moderna has begun discussions with Switzerland over a so-called vaccine subscription that could ensure supply as it develops novel mRNA vaccine, and is interested in deepening ties with other regimes.</p>\n<p>\"We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease that is fatal in the elderly and young children,\" Bancel said.</p>\n<p>\"We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.\"</p>\n<p>That would give those countries priority supply in the event of a new pandemic, he said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140916492","content_text":"ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few weeks, Chief Executive Stephane Bancel said in an interview.\nModerna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose of its current mRNA-1273 vaccine.\n\"It only needs minor adjustments for Omicron. I don't expect any problems,\" Bancel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.\nThe company was now awaiting important information on the variant to begin development.\n\"That will take another week or two,\" Bancel said.\n\"It will take a few months before we can produce 500 million doses after (regulatory) approval. But our capacities are much higher today than a year ago,\" he said.\nIf approval bodies such as the U.S. Food and Drug Administration and Switzerland's Swissmedic require further studies, that would add at least three months.\n\"Some authorities want a study, others are still undecided. In my opinion, it depends very much on how severely the disease progresses,\" he said.\nFollowing delivery delays and lags in production in early 2021, Moderna is now able to keep up with production targets and deliver orders on time.\nThe company made between 700 million and 800 million COVID-19 vaccine doses this year, and expects to produce a higher number in 2022, boosting production from 100 million doses a month to 150 million.\nAdditional production lines that are being built via a deal with Swiss-based drugmaker Lonza will become operational in the first quarter of 2022, boosting production, he said, adding the company for the first time had 30 million doses in stock.\nAfter signing preliminary agreements with Canada and Australia, Moderna has begun discussions with Switzerland over a so-called vaccine subscription that could ensure supply as it develops novel mRNA vaccine, and is interested in deepening ties with other regimes.\n\"We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease that is fatal in the elderly and young children,\" Bancel said.\n\"We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.\"\nThat would give those countries priority supply in the event of a new pandemic, he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693412964,"gmtCreate":1640060631521,"gmtModify":1640063741817,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&amp;utm_medium=social&amp;utm_source=facebook&amp;fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&amp;utm_medium=social&amp;utm_source=facebook&amp;fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk","text":"$Moderna, Inc.(MRNA)$https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&utm_medium=social&utm_source=facebook&fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693412964","isVote":1,"tweetType":1,"viewCount":939,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479274800160907","authorId":"3479274800160907","name":"yeppy","avatar":"https://static.laohu8.com/picture153","crmLevel":1,"crmLevelSwitch":0},"content":"现在可以考虑放弃疫苗库存了。","text":"现在可以考虑放弃疫苗库存了。","html":"现在可以考虑放弃疫苗库存了。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699322955,"gmtCreate":1639751579036,"gmtModify":1639751579787,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi this is for event&nbsp;","listText":"Hi this is for event&nbsp;","text":"Hi this is for event","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699322955","isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699323580,"gmtCreate":1639751317454,"gmtModify":1639751432372,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Isn’t this old news&nbsp;","listText":"Isn’t this old news&nbsp;","text":"Isn’t this old news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699323580","repostId":"2192592765","repostType":2,"repost":{"id":"2192592765","pubTimestamp":1639739564,"share":"https://www.laohu8.com/m/news/2192592765?lang=&edition=full","pubTime":"2021-12-17 19:12","market":"us","language":"en","title":"Moderna COVID-19 shot more likely to cause heart inflammation than Pfizer's, study shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2192592765","media":"Reuters","summary":"Moderna's COVID-19 vaccine is up to four times more likely to cause inflammation of the heart muscle","content":"<p>Moderna's COVID-19 vaccine is up to four times more likely to cause inflammation of the heart muscle, a very rare side effect, than its rival vaccine from Pfizer-BioNTech , according to a Danish study published in the British Medical Journal late on Thursday.</p>\n<p>The study, in which almost 85% of Danes, or 4.9 million individuals, aged 12 and older participated, investigated the link between mRNA-based COVID-19 vaccines and heart inflammation, also known as myocarditis or myopericarditis.</p>\n<p>Earlier studies from Israel and the United States have indicated an increased risk of heart inflammation after inoculation with the mRNA-vaccines developed by Pfizer-BioNTech and Moderna.</p>\n<p>\"Vaccination with mRNA-1273 (Moderna's vaccine) was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population,\" the study said.</p>\n<p>However, the overall risk of getting heart inflammation from the vaccines, both of which are based on mRNA-technology, was low, according to the study, conducted by researchers from Denmark's Statens Serum Institute.</p>\n<p>\"In general, the rate of myocarditis or myopericarditis was about threefold to fourfold higher for mRNA-1273 (Moderna) vaccination than that for BNT162b2 (Pfizer-BioNTech) vaccination,\" the study said.</p>\n<p>The researchers found only 1 case per 71,400 vaccinated with Pfizer-BioNTech and 1 case per 23,800 vaccinated with Moderna. Most of the cases had been mild, the study said.</p>\n<p>Pfizer-BioNTech's vaccine was only associated with a higher risk of heart inflammation among women, the study said, contrasting with the results of the studies from Israel and the United States.</p>\n<p>The authors said the discrepancy could be explained by the average age of the vaccinated population, time span between the first and second shot or because fewer Danes had tested positive for COVID-19.</p>\n<p>\"Our findings do not generally overshadow the many benefits that come with being vaccinated,\" study author Anders Hviid said in a statement.</p>\n<p>\"One must keep in mind that the alternative of getting an infection with COVID-19 probably also involves a risk of inflammation in the heart muscle,\" Hviid said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 shot more likely to cause heart inflammation than Pfizer's, study shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 shot more likely to cause heart inflammation than Pfizer's, study shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 19:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-covid-19-shot-more-103540062.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna's COVID-19 vaccine is up to four times more likely to cause inflammation of the heart muscle, a very rare side effect, than its rival vaccine from Pfizer-BioNTech , according to a Danish study...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-covid-19-shot-more-103540062.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","MRNA":"Moderna, Inc.","BK4548":"巴美列捷福持仓","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://finance.yahoo.com/news/moderna-covid-19-shot-more-103540062.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2192592765","content_text":"Moderna's COVID-19 vaccine is up to four times more likely to cause inflammation of the heart muscle, a very rare side effect, than its rival vaccine from Pfizer-BioNTech , according to a Danish study published in the British Medical Journal late on Thursday.\nThe study, in which almost 85% of Danes, or 4.9 million individuals, aged 12 and older participated, investigated the link between mRNA-based COVID-19 vaccines and heart inflammation, also known as myocarditis or myopericarditis.\nEarlier studies from Israel and the United States have indicated an increased risk of heart inflammation after inoculation with the mRNA-vaccines developed by Pfizer-BioNTech and Moderna.\n\"Vaccination with mRNA-1273 (Moderna's vaccine) was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population,\" the study said.\nHowever, the overall risk of getting heart inflammation from the vaccines, both of which are based on mRNA-technology, was low, according to the study, conducted by researchers from Denmark's Statens Serum Institute.\n\"In general, the rate of myocarditis or myopericarditis was about threefold to fourfold higher for mRNA-1273 (Moderna) vaccination than that for BNT162b2 (Pfizer-BioNTech) vaccination,\" the study said.\nThe researchers found only 1 case per 71,400 vaccinated with Pfizer-BioNTech and 1 case per 23,800 vaccinated with Moderna. Most of the cases had been mild, the study said.\nPfizer-BioNTech's vaccine was only associated with a higher risk of heart inflammation among women, the study said, contrasting with the results of the studies from Israel and the United States.\nThe authors said the discrepancy could be explained by the average age of the vaccinated population, time span between the first and second shot or because fewer Danes had tested positive for COVID-19.\n\"Our findings do not generally overshadow the many benefits that come with being vaccinated,\" study author Anders Hviid said in a statement.\n\"One must keep in mind that the alternative of getting an infection with COVID-19 probably also involves a risk of inflammation in the heart muscle,\" Hviid said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606248914,"gmtCreate":1638888525088,"gmtModify":1638888527015,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.&nbsp;","text":"$Moderna, Inc.(MRNA)$Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606248914","isVote":1,"tweetType":1,"viewCount":1061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601586324,"gmtCreate":1638542850367,"gmtModify":1638542850713,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Haha once again people selling even with good news. [Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Haha once again people selling even with good news. [Miser]&nbsp;","text":"$Moderna, Inc.(MRNA)$Haha once again people selling even with good news. [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/601586324","isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603130181,"gmtCreate":1638371876761,"gmtModify":1638372085647,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy both&nbsp;","listText":"Buy both&nbsp;","text":"Buy both","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603130181","repostId":"1119742422","repostType":2,"repost":{"id":"1119742422","pubTimestamp":1638368504,"share":"https://www.laohu8.com/m/news/1119742422?lang=&edition=full","pubTime":"2021-12-01 22:21","market":"us","language":"en","title":"Moderna or Pfizer Stock: Which to Buy as Omicron Spreads? ","url":"https://stock-news.laohu8.com/highlight/detail?id=1119742422","media":"TheStreet","summary":"Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks ","content":"<p>Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks are back in the spotlight. Today, we take a closer look at Moderna and Pfizer stocks.</p>\n<p>COVID-19 keeps haunting the markets. New variant Omicron has renewed fears worldwide about a new health and economic crisis, since little is still known about how this variant affects vaccinated and non-vaccinated people.</p>\n<p>The stock market sold off on Friday, November 26, after Omicron news hit the wire. The S&amp;P 500&nbsp;dropped 2% amid uncertainty. One of the few gainers was Moderna stock, which jumped 20% on Friday’s trading session, while Pfizer stock&nbsp;was up a more modest 2.5%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b55d87c377ec124bb84173bfb955b9fa\" tg-width=\"689\" tg-height=\"621\" width=\"100%\" height=\"auto\"><span>Figure 1: SPY, MRNA and PFE performance in the past 5-trading days.</span></p>\n<p>Between two of the main COVID-19 vaccine makers, we assess Moderna and Pfizer stocks and ask ourselves: which is a better buy as Omicron fear lingers?</p>\n<p><b>Wall Street is neutral on Moderna</b></p>\n<p>Moderna stock currently has a hold consensus among 13 analysts and an average price target of $298, which suggests 17% downside from current levels. Wall Street’s assessment suggests that the stock price may have moved ahead of fundamentals, as MRNA has gained more than 1,200% since the COVID-19 pandemic started.</p>\n<p>The most recent report on Moderna stock came from Piper Sandler’s Edward Tenthoff, who&nbsp;reiterated&nbsp;his buy recommendation and forecasted a $348 price target on the back of Omicron news. The analyst sees the company prepared for the emergence of new variants and \"ideally suited to rapidly swap in new versions of the Spike antigen\" to make new COVID-19 vaccines.</p>\n<p>Morgan Stanley’s Matthew Harrison&nbsp;reiterated&nbsp;his neutral rating on MRNA a week ago with a $313 price target. The analyst mentioned that the announcement of Moderna’s flu vaccine data before year-end could be a positive catalyst for the stock. If the results are positive, the market could price in about $10 billion in long-term flu and COVID vaccine revenue, bumping shares by 10%.</p>\n<p><b>Pfizer: moderate buy, but experts are skeptical</b></p>\n<p>Wall Street is currently bullish on Pfizer, based on stock ratings. However, average price target consensus suggests that valuations could be stretched thin, following the November rally. PFE has a moderate buy recommendation based on 13 reports and a $50 average price target.</p>\n<p>JPMorgan‘s Chris Schott&nbsp;raised&nbsp;the firm's price target on Pfizer to $53 from $42 and kept a neutral rating. Covid remains a focal point of the Pfizer story, and Comirnaty and Paxlovid sales are \"set to clearly exceed expectations”. While the analyst sees limited upside from the company's core business, he would not be surprised to see shares rally in the near-term on omicron headlines.</p>\n<p>The most recent update on PFE came from Mizuho Securities’ Vamil Divan. He is&nbsp;skeptical&nbsp;on Pfizer stock and sees 16% downside risk. But according to the analyst, Omicron may increase near-term demand for Pfizer’s COVID-19 vaccine, especially for booster doses.</p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>COVID-19 vaccine makers may naturally benefit in the near-term from Omicron fears. Moderna, for instance, has risen more than 1,200% since the beginning of the COVID-19 pandemic in March 2020, while Pfizer stock has climbed 79% during the same period.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/198c43532bf2d097bc94e078b539a044\" tg-width=\"684\" tg-height=\"577\" width=\"100%\" height=\"auto\"><span>Figure 2: MRNA and PFE performance in the past 5-years.</span></p>\n<p>Pfizer is much larger than Moderna, with a market cap size of $300 billion compared to Moderna’s $133 billion. Both companies have strong vaccine pipelines and technology, but Moderna likely benefits from the current pandemic for being more of a pure-play stock.</p>\n<p>Due to business model diversification, we see MRNA as a better short-term bet on COVID-19 developments. However, for this same reason and due to richer 2023 P/E of 32x, the stock is likely to be more volatile and present higher downside risk. PFE, on the other hand, could be a better long-term bet on healthcare at large, especially considering de-risked 2023 P/E of only 13x.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna or Pfizer Stock: Which to Buy as Omicron Spreads? </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna or Pfizer Stock: Which to Buy as Omicron Spreads? \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/reddit-trends/moderna-or-pfizer-stock-which-to-buy-as-omicron-spreads><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks are back in the spotlight. Today, we take a closer look at Moderna and Pfizer stocks.\nCOVID-19 keeps...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/reddit-trends/moderna-or-pfizer-stock-which-to-buy-as-omicron-spreads\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.thestreet.com/memestocks/reddit-trends/moderna-or-pfizer-stock-which-to-buy-as-omicron-spreads","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119742422","content_text":"Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks are back in the spotlight. Today, we take a closer look at Moderna and Pfizer stocks.\nCOVID-19 keeps haunting the markets. New variant Omicron has renewed fears worldwide about a new health and economic crisis, since little is still known about how this variant affects vaccinated and non-vaccinated people.\nThe stock market sold off on Friday, November 26, after Omicron news hit the wire. The S&P 500 dropped 2% amid uncertainty. One of the few gainers was Moderna stock, which jumped 20% on Friday’s trading session, while Pfizer stock was up a more modest 2.5%.\nFigure 1: SPY, MRNA and PFE performance in the past 5-trading days.\nBetween two of the main COVID-19 vaccine makers, we assess Moderna and Pfizer stocks and ask ourselves: which is a better buy as Omicron fear lingers?\nWall Street is neutral on Moderna\nModerna stock currently has a hold consensus among 13 analysts and an average price target of $298, which suggests 17% downside from current levels. Wall Street’s assessment suggests that the stock price may have moved ahead of fundamentals, as MRNA has gained more than 1,200% since the COVID-19 pandemic started.\nThe most recent report on Moderna stock came from Piper Sandler’s Edward Tenthoff, who reiterated his buy recommendation and forecasted a $348 price target on the back of Omicron news. The analyst sees the company prepared for the emergence of new variants and \"ideally suited to rapidly swap in new versions of the Spike antigen\" to make new COVID-19 vaccines.\nMorgan Stanley’s Matthew Harrison reiterated his neutral rating on MRNA a week ago with a $313 price target. The analyst mentioned that the announcement of Moderna’s flu vaccine data before year-end could be a positive catalyst for the stock. If the results are positive, the market could price in about $10 billion in long-term flu and COVID vaccine revenue, bumping shares by 10%.\nPfizer: moderate buy, but experts are skeptical\nWall Street is currently bullish on Pfizer, based on stock ratings. However, average price target consensus suggests that valuations could be stretched thin, following the November rally. PFE has a moderate buy recommendation based on 13 reports and a $50 average price target.\nJPMorgan‘s Chris Schott raised the firm's price target on Pfizer to $53 from $42 and kept a neutral rating. Covid remains a focal point of the Pfizer story, and Comirnaty and Paxlovid sales are \"set to clearly exceed expectations”. While the analyst sees limited upside from the company's core business, he would not be surprised to see shares rally in the near-term on omicron headlines.\nThe most recent update on PFE came from Mizuho Securities’ Vamil Divan. He is skeptical on Pfizer stock and sees 16% downside risk. But according to the analyst, Omicron may increase near-term demand for Pfizer’s COVID-19 vaccine, especially for booster doses.\nWall Street Memes’ take\nCOVID-19 vaccine makers may naturally benefit in the near-term from Omicron fears. Moderna, for instance, has risen more than 1,200% since the beginning of the COVID-19 pandemic in March 2020, while Pfizer stock has climbed 79% during the same period.\nFigure 2: MRNA and PFE performance in the past 5-years.\nPfizer is much larger than Moderna, with a market cap size of $300 billion compared to Moderna’s $133 billion. Both companies have strong vaccine pipelines and technology, but Moderna likely benefits from the current pandemic for being more of a pure-play stock.\nDue to business model diversification, we see MRNA as a better short-term bet on COVID-19 developments. However, for this same reason and due to richer 2023 P/E of 32x, the stock is likely to be more volatile and present higher downside risk. PFE, on the other hand, could be a better long-term bet on healthcare at large, especially considering de-risked 2023 P/E of only 13x.","news_type":1},"isVote":1,"tweetType":1,"viewCount":683,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603376520,"gmtCreate":1638370453375,"gmtModify":1638370454523,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Paper hand&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Paper hand&nbsp;","text":"$Moderna, Inc.(MRNA)$Paper hand","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603376520","isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609676668,"gmtCreate":1638283443289,"gmtModify":1638283450501,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>price is trading too high when is not authorised. I would close position to get into moderna or Pfizer","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>price is trading too high when is not authorised. I would close position to get into moderna or Pfizer","text":"$Novavax(NVAX)$price is trading too high when is not authorised. I would close position to get into moderna or Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609676668","isVote":1,"tweetType":1,"viewCount":1282,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575034124594582","authorId":"3575034124594582","name":"Andarian","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"content":"欺诈新闻只做了昨晚的事。此后又有强大的后援。我真想知道。","text":"欺诈新闻只做了昨晚的事。此后又有强大的后援。我真想知道。","html":"欺诈新闻只做了昨晚的事。此后又有强大的后援。我真想知道。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609887686,"gmtCreate":1638265033493,"gmtModify":1638265033818,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year&nbsp;","text":"$Moderna, Inc.(MRNA)$Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/609887686","isVote":1,"tweetType":1,"viewCount":1073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600453968,"gmtCreate":1638191484516,"gmtModify":1638191485692,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Is time to buy in because of omicron haha:)&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Is time to buy in because of omicron haha:)&nbsp;","text":"$Moderna, Inc.(MRNA)$Is time to buy in because of omicron haha:)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600453968","isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878807177,"gmtCreate":1637162992090,"gmtModify":1637162992476,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Growth is growth. Will you rather invest in a company that make loss or company with so called maybe&nbsp;decelerating growth. My view is palantir has the potential to work with different big companies.&nbsp;","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Growth is growth. Will you rather invest in a company that make loss or company with so called maybe&nbsp;decelerating growth. My view is palantir has the potential to work with different big companies.&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$Growth is growth. Will you rather invest in a company that make loss or company with so called maybe decelerating growth. My view is palantir has the potential to work with different big companies.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878807177","isVote":1,"tweetType":1,"viewCount":2569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870412882,"gmtCreate":1636641938267,"gmtModify":1636641948272,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Timeline is very important. Clearly, if ocugen has not gotten approval by now then is really time to leave if you have profit. Those who hold might want to get option to sell … I foresee is going down&nbsp;","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Timeline is very important. Clearly, if ocugen has not gotten approval by now then is really time to leave if you have profit. Those who hold might want to get option to sell … I foresee is going down&nbsp;","text":"$Histogenics(OCGN)$Timeline is very important. Clearly, if ocugen has not gotten approval by now then is really time to leave if you have profit. Those who hold might want to get option to sell … I foresee is going down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870412882","isVote":1,"tweetType":1,"viewCount":1748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870438498,"gmtCreate":1636641529342,"gmtModify":1636641530420,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>Lol if u havealready profit, please run. This is very risky~","listText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>Lol if u havealready profit, please run. This is very risky~","text":"$Rivian Automotive, Inc.(RIVN)$Lol if u havealready profit, please run. This is very risky~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870438498","isVote":1,"tweetType":1,"viewCount":715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847489471,"gmtCreate":1636545252708,"gmtModify":1636545253842,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>The price is too high. Poor valuation&nbsp;","listText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>The price is too high. Poor valuation&nbsp;","text":"$Rivian Automotive, Inc.(RIVN)$The price is too high. Poor valuation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847489471","isVote":1,"tweetType":1,"viewCount":59,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847040450,"gmtCreate":1636469666066,"gmtModify":1636470314480,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>Jokers selling. Haha. Sometime is hard to find news&nbsp;","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>Jokers selling. Haha. Sometime is hard to find news&nbsp;","text":"$Intel(INTC)$Jokers selling. Haha. Sometime is hard to find news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847040450","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844755419,"gmtCreate":1636463939821,"gmtModify":1636463940889,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>IPO surge is over. Thanks it was a good run:) 30% from 46+. Regret didn’t get in more !&nbsp;","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>IPO surge is over. Thanks it was a good run:) 30% from 46+. Regret didn’t get in more !&nbsp;","text":"$GLOBALFOUNDRIES Inc.(GFS)$IPO surge is over. Thanks it was a good run:) 30% from 46+. Regret didn’t get in more !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844755419","isVote":1,"tweetType":1,"viewCount":312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844958914,"gmtCreate":1636384469146,"gmtModify":1636384475839,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Isn’t this good news haha&nbsp;","listText":"Isn’t this good news haha&nbsp;","text":"Isn’t this good news haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844958914","repostId":"1146420549","repostType":2,"repost":{"id":"1146420549","pubTimestamp":1636375500,"share":"https://www.laohu8.com/m/news/1146420549?lang=&edition=full","pubTime":"2021-11-08 20:45","market":"us","language":"en","title":"Why Are GlobalFoundries Shares Trading Lower Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1146420549","media":"Benzinga","summary":"The Pentagon plans to place up to $2 billion in rush orders by early March for customized semiconduc","content":"<ul>\n <li>The Pentagon plans to place up to $2 billion in rush orders by early March for customized semiconductors used in weapons like the B-2 bomber before the shut down of production line,&nbsp;Bloomberg reports.</li>\n <li><b>Globalfoundries Inc</b>&nbsp;sold the factory in Fishkill, New York, that produced the specialized chips used in GPS-dependent systems to&nbsp;<b>ON Semiconductor Corp</b>. The new owner will not make any more of them.</li>\n <li>The Defense Department is confronting its looming supply crunch amid a global chip crisis used in consumer items from mobile phones to autonomous vehicles, markets where GlobalFoundries is expanding its production.</li>\n <li>The Pentagon would place an initial $885 million by December 15 with U.S. contractors. The Pentagon would have to place the remainder of the $2 billion in orders by March 3, the report added.</li>\n <li>“For certain programs and technologies, we are meeting the DoD’s needs by manufacturing large volumes of chips sufficient for the lifetime of the program,” GlobalFoundries said.</li>\n <li>“In other instances, we are partnering with the DoD to extend the lifecycle of certain technologies manufactured at Fab 10 by transitioning the manufacturing of their chips to other GF Fabs.”</li>\n <li><b>Price Action:</b>&nbsp;GFS shares traded lower by 4.49% to $60.77 in the premarket session on the last check Monday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are GlobalFoundries Shares Trading Lower Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are GlobalFoundries Shares Trading Lower Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/government/21/11/23947108/why-are-globalfoundries-shares-trading-lower-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Pentagon plans to place up to $2 billion in rush orders by early March for customized semiconductors used in weapons like the B-2 bomber before the shut down of production line, Bloomberg reports....</p>\n\n<a href=\"https://www.benzinga.com/government/21/11/23947108/why-are-globalfoundries-shares-trading-lower-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GFS":"GLOBALFOUNDRIES Inc."},"source_url":"https://www.benzinga.com/government/21/11/23947108/why-are-globalfoundries-shares-trading-lower-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146420549","content_text":"The Pentagon plans to place up to $2 billion in rush orders by early March for customized semiconductors used in weapons like the B-2 bomber before the shut down of production line, Bloomberg reports.\nGlobalfoundries Inc sold the factory in Fishkill, New York, that produced the specialized chips used in GPS-dependent systems to ON Semiconductor Corp. The new owner will not make any more of them.\nThe Defense Department is confronting its looming supply crunch amid a global chip crisis used in consumer items from mobile phones to autonomous vehicles, markets where GlobalFoundries is expanding its production.\nThe Pentagon would place an initial $885 million by December 15 with U.S. contractors. The Pentagon would have to place the remainder of the $2 billion in orders by March 3, the report added.\n“For certain programs and technologies, we are meeting the DoD’s needs by manufacturing large volumes of chips sufficient for the lifetime of the program,” GlobalFoundries said.\n“In other instances, we are partnering with the DoD to extend the lifecycle of certain technologies manufactured at Fab 10 by transitioning the manufacturing of their chips to other GF Fabs.”\nPrice Action: GFS shares traded lower by 4.49% to $60.77 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844929368,"gmtCreate":1636383994873,"gmtModify":1636383996493,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Hodl and push to 70&nbsp;","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Hodl and push to 70&nbsp;","text":"$GLOBALFOUNDRIES Inc.(GFS)$Hodl and push to 70","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844929368","isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":846119960,"gmtCreate":1636067278704,"gmtModify":1636067279722,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NRXP\">$NRX Pharmaceuticals Inc.(NRXP)$</a>What is with the sudden aftermarket drop","listText":"<a href=\"https://laohu8.com/S/NRXP\">$NRX Pharmaceuticals Inc.(NRXP)$</a>What is with the sudden aftermarket drop","text":"$NRX Pharmaceuticals Inc.(NRXP)$What is with the sudden aftermarket drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/846119960","isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4088972556421510","authorId":"4088972556421510","name":"最近满地是坑","avatar":"https://static.tigerbbs.com/948c089818d4e7dc735d11b260333f8e","crmLevel":1,"crmLevelSwitch":0},"content":"只是说药物～并没有说疫苗","text":"只是说药物～并没有说疫苗","html":"只是说药物～并没有说疫苗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":187581731,"gmtCreate":1623759029423,"gmtModify":1631883740138,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> 今晚如果没有怪操作，应该$8 。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> 今晚如果没有怪操作，应该$8 。","text":"$Histogenics(OCGN)$ 今晚如果没有怪操作，应该$8 。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/187581731","isVote":1,"tweetType":1,"viewCount":996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168047612,"gmtCreate":1623945679036,"gmtModify":1631885815341,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>想再进。明天开盘前，飙","listText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>想再进。明天开盘前，飙","text":"$BlackBerry(BB)$想再进。明天开盘前，飙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/168047612","isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601586324,"gmtCreate":1638542850367,"gmtModify":1638542850713,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Haha once again people selling even with good news. [Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Haha once again people selling even with good news. [Miser]&nbsp;","text":"$Moderna, Inc.(MRNA)$Haha once again people selling even with good news. [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/601586324","isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609676668,"gmtCreate":1638283443289,"gmtModify":1638283450501,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>price is trading too high when is not authorised. I would close position to get into moderna or Pfizer","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>price is trading too high when is not authorised. I would close position to get into moderna or Pfizer","text":"$Novavax(NVAX)$price is trading too high when is not authorised. I would close position to get into moderna or Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609676668","isVote":1,"tweetType":1,"viewCount":1282,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575034124594582","authorId":"3575034124594582","name":"Andarian","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"content":"欺诈新闻只做了昨晚的事。此后又有强大的后援。我真想知道。","text":"欺诈新闻只做了昨晚的事。此后又有强大的后援。我真想知道。","html":"欺诈新闻只做了昨晚的事。此后又有强大的后援。我真想知道。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693412964,"gmtCreate":1640060631521,"gmtModify":1640063741817,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&amp;utm_medium=social&amp;utm_source=facebook&amp;fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&amp;utm_medium=social&amp;utm_source=facebook&amp;fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk","text":"$Moderna, Inc.(MRNA)$https://www.straitstimes.com/world/united-states/moderna-says-booster-dose-of-its-covid-19-vaccine-appears-protective-against-omicron?utm_campaign=stfb&utm_medium=social&utm_source=facebook&fbclid=IwAR26_zEAW-L0uTy-8r2p26TGIAh1EH9oyStzloft8HaSaRYVUdgp98iIbyk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693412964","isVote":1,"tweetType":1,"viewCount":939,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479274800160907","authorId":"3479274800160907","name":"yeppy","avatar":"https://static.laohu8.com/picture153","crmLevel":1,"crmLevelSwitch":0},"content":"现在可以考虑放弃疫苗库存了。","text":"现在可以考虑放弃疫苗库存了。","html":"现在可以考虑放弃疫苗库存了。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609887686,"gmtCreate":1638265033493,"gmtModify":1638265033818,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year&nbsp;","text":"$Moderna, Inc.(MRNA)$Wow tigerpress is manipulating haha. Anw the existing vaccine is not as effective against omicron. I expect Pfizerto be so that is why both are working in new vaccine which the moderna ppl said it will be early next year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/609887686","isVote":1,"tweetType":1,"viewCount":1073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878807177,"gmtCreate":1637162992090,"gmtModify":1637162992476,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Growth is growth. Will you rather invest in a company that make loss or company with so called maybe&nbsp;decelerating growth. My view is palantir has the potential to work with different big companies.&nbsp;","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Growth is growth. Will you rather invest in a company that make loss or company with so called maybe&nbsp;decelerating growth. My view is palantir has the potential to work with different big companies.&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$Growth is growth. Will you rather invest in a company that make loss or company with so called maybe decelerating growth. My view is palantir has the potential to work with different big companies.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878807177","isVote":1,"tweetType":1,"viewCount":2569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693790079,"gmtCreate":1640073868484,"gmtModify":1640073869178,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Fly","listText":"Fly","text":"Fly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693790079","repostId":"1140916492","repostType":2,"repost":{"id":"1140916492","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640072746,"share":"https://www.laohu8.com/m/news/1140916492?lang=&edition=full","pubTime":"2021-12-21 15:45","market":"us","language":"en","title":"Moderna could be ready to develop Omicron booster in weeks - CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1140916492","media":"Reuters","summary":"ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing","content":"<p>ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few weeks, Chief Executive Stephane Bancel said in an interview.</p>\n<p>Moderna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose&nbsp;of its current mRNA-1273 vaccine.</p>\n<p>\"It only needs minor adjustments for Omicron. I don't expect any problems,\" Bancel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.</p>\n<p>The company was now awaiting important information on the variant to begin development.</p>\n<p>\"That will take another week or two,\" Bancel said.</p>\n<p>\"It will take a few months before we can produce 500 million doses after (regulatory) approval. But our capacities are much higher today than a year ago,\" he said.</p>\n<p>If approval bodies such as the U.S. Food and Drug Administration and Switzerland's Swissmedic require further studies, that would add at least three months.</p>\n<p>\"Some authorities want a study, others are still undecided. In my opinion, it depends very much on how severely the disease progresses,\" he said.</p>\n<p>Following delivery delays and lags in production in early 2021, Moderna is now able to keep up with production targets and deliver orders on time.</p>\n<p>The company made between 700 million and 800 million COVID-19 vaccine doses this year, and expects to produce a higher number in 2022, boosting production from 100 million doses a month to 150 million.</p>\n<p>Additional production lines that are being built via a deal with Swiss-based drugmaker Lonza will become operational in the first quarter of 2022, boosting production, he said, adding the company for the first time had 30 million doses in stock.</p>\n<p>After signing preliminary agreements with Canada and Australia, Moderna has begun discussions with Switzerland over a so-called vaccine subscription that could ensure supply as it develops novel mRNA vaccine, and is interested in deepening ties with other regimes.</p>\n<p>\"We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease that is fatal in the elderly and young children,\" Bancel said.</p>\n<p>\"We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.\"</p>\n<p>That would give those countries priority supply in the event of a new pandemic, he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna could be ready to develop Omicron booster in weeks - CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna could be ready to develop Omicron booster in weeks - CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-21 15:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few weeks, Chief Executive Stephane Bancel said in an interview.</p>\n<p>Moderna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose&nbsp;of its current mRNA-1273 vaccine.</p>\n<p>\"It only needs minor adjustments for Omicron. I don't expect any problems,\" Bancel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.</p>\n<p>The company was now awaiting important information on the variant to begin development.</p>\n<p>\"That will take another week or two,\" Bancel said.</p>\n<p>\"It will take a few months before we can produce 500 million doses after (regulatory) approval. But our capacities are much higher today than a year ago,\" he said.</p>\n<p>If approval bodies such as the U.S. Food and Drug Administration and Switzerland's Swissmedic require further studies, that would add at least three months.</p>\n<p>\"Some authorities want a study, others are still undecided. In my opinion, it depends very much on how severely the disease progresses,\" he said.</p>\n<p>Following delivery delays and lags in production in early 2021, Moderna is now able to keep up with production targets and deliver orders on time.</p>\n<p>The company made between 700 million and 800 million COVID-19 vaccine doses this year, and expects to produce a higher number in 2022, boosting production from 100 million doses a month to 150 million.</p>\n<p>Additional production lines that are being built via a deal with Swiss-based drugmaker Lonza will become operational in the first quarter of 2022, boosting production, he said, adding the company for the first time had 30 million doses in stock.</p>\n<p>After signing preliminary agreements with Canada and Australia, Moderna has begun discussions with Switzerland over a so-called vaccine subscription that could ensure supply as it develops novel mRNA vaccine, and is interested in deepening ties with other regimes.</p>\n<p>\"We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease that is fatal in the elderly and young children,\" Bancel said.</p>\n<p>\"We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.\"</p>\n<p>That would give those countries priority supply in the event of a new pandemic, he said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140916492","content_text":"ZURICH, Dec 21 (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few weeks, Chief Executive Stephane Bancel said in an interview.\nModerna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose of its current mRNA-1273 vaccine.\n\"It only needs minor adjustments for Omicron. I don't expect any problems,\" Bancel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.\nThe company was now awaiting important information on the variant to begin development.\n\"That will take another week or two,\" Bancel said.\n\"It will take a few months before we can produce 500 million doses after (regulatory) approval. But our capacities are much higher today than a year ago,\" he said.\nIf approval bodies such as the U.S. Food and Drug Administration and Switzerland's Swissmedic require further studies, that would add at least three months.\n\"Some authorities want a study, others are still undecided. In my opinion, it depends very much on how severely the disease progresses,\" he said.\nFollowing delivery delays and lags in production in early 2021, Moderna is now able to keep up with production targets and deliver orders on time.\nThe company made between 700 million and 800 million COVID-19 vaccine doses this year, and expects to produce a higher number in 2022, boosting production from 100 million doses a month to 150 million.\nAdditional production lines that are being built via a deal with Swiss-based drugmaker Lonza will become operational in the first quarter of 2022, boosting production, he said, adding the company for the first time had 30 million doses in stock.\nAfter signing preliminary agreements with Canada and Australia, Moderna has begun discussions with Switzerland over a so-called vaccine subscription that could ensure supply as it develops novel mRNA vaccine, and is interested in deepening ties with other regimes.\n\"We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease that is fatal in the elderly and young children,\" Bancel said.\n\"We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.\"\nThat would give those countries priority supply in the event of a new pandemic, he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825209321,"gmtCreate":1634224764061,"gmtModify":1634224764377,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Tomorrow will have a better performance. The troll has begun&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Tomorrow will have a better performance. The troll has begun&nbsp;","text":"$AMC Entertainment(AMC)$Tomorrow will have a better performance. The troll has begun","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825209321","isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168072072,"gmtCreate":1623945803596,"gmtModify":1631886598436,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>買入吧大家！ 不要怕","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>買入吧大家！ 不要怕","text":"$Nano Dimension(NNDM)$買入吧大家！ 不要怕","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/168072072","isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":187531608,"gmtCreate":1623758179304,"gmtModify":1631883740161,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> This clearly shows the confidence <a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> of obtaining the approval. The idea of securing Manufacturing Partnership for US Production has taken place is definitely good news and might also mean that there is very huge progress of FDA /BCA approval which is why they are looking at mass producing. Profit is coming! I am buying in more before it moons[财迷] [财迷]","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> This clearly shows the confidence <a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> of obtaining the approval. The idea of securing Manufacturing Partnership for US Production has taken place is definitely good news and might also mean that there is very huge progress of FDA /BCA approval which is why they are looking at mass producing. Profit is coming! I am buying in more before it moons[财迷] [财迷]","text":"$Histogenics(OCGN)$ This clearly shows the confidence $Histogenics(OCGN)$ of obtaining the approval. The idea of securing Manufacturing Partnership for US Production has taken place is definitely good news and might also mean that there is very huge progress of FDA /BCA approval which is why they are looking at mass producing. Profit is coming! I am buying in more before it moons[财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187531608","isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691019636,"gmtCreate":1640097345384,"gmtModify":1640097346158,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>I don’t even know who is selling this? Haha&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>I don’t even know who is selling this? Haha&nbsp;","text":"$Moderna, Inc.(MRNA)$I don’t even know who is selling this? Haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/691019636","isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606248914,"gmtCreate":1638888525088,"gmtModify":1638888527015,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.&nbsp;","text":"$Moderna, Inc.(MRNA)$Apparently, vaccine only last for a period of time so we constantly need booster shot. Getting mine soon ~. Wow this look lucrative for vaccine makers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606248914","isVote":1,"tweetType":1,"viewCount":1061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854693366,"gmtCreate":1635438361879,"gmtModify":1635438363007,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>AMC is literallyyou buying and seeing red and leave it. You just don’t know which day the market go crazy and for it to see sudden surge.&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>AMC is literallyyou buying and seeing red and leave it. You just don’t know which day the market go crazy and for it to see sudden surge.&nbsp;","text":"$AMC Entertainment(AMC)$AMC is literallyyou buying and seeing red and leave it. You just don’t know which day the market go crazy and for it to see sudden surge.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854693366","isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870438498,"gmtCreate":1636641529342,"gmtModify":1636641530420,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>Lol if u havealready profit, please run. This is very risky~","listText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>Lol if u havealready profit, please run. This is very risky~","text":"$Rivian Automotive, Inc.(RIVN)$Lol if u havealready profit, please run. This is very risky~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870438498","isVote":1,"tweetType":1,"viewCount":715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844042266,"gmtCreate":1636380454659,"gmtModify":1636380465668,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Why is themarket not open yet&nbsp;","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Why is themarket not open yet&nbsp;","text":"$GLOBALFOUNDRIES Inc.(GFS)$Why is themarket not open yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844042266","isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":130605606,"gmtCreate":1621527907405,"gmtModify":1634188361361,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>疯了我喜欢","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>疯了我喜欢","text":"$XPeng Inc.(XPEV)$疯了我喜欢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/130605606","isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844958914,"gmtCreate":1636384469146,"gmtModify":1636384475839,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Isn’t this good news haha&nbsp;","listText":"Isn’t this good news haha&nbsp;","text":"Isn’t this good news haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844958914","repostId":"1146420549","repostType":2,"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854690420,"gmtCreate":1635438205221,"gmtModify":1635438206169,"author":{"id":"3581759532939362","authorId":"3581759532939362","name":"Jinyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NRXP\">$NRX Pharmaceuticals Inc.(NRXP)$</a>This is another ocugen. Believe me I have seen it before haha. You need to be patient to hold. Not for weeks but months&nbsp;","listText":"<a href=\"https://laohu8.com/S/NRXP\">$NRX Pharmaceuticals Inc.(NRXP)$</a>This is another ocugen. Believe me I have seen it before haha. You need to be patient to hold. Not for weeks but months&nbsp;","text":"$NRX Pharmaceuticals Inc.(NRXP)$This is another ocugen. Believe me I have seen it before haha. You need to be patient to hold. Not for weeks but months","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854690420","isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}